Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML--a case report.
A patient, who was treated twice with donor lymphocyte infusions for relapse of CML after an allogeneic BMT was given lymphoblastoid human alpha-IFN after a third relapse. Further donor lymphocyte infusions were followed by repeated courses of 30 days treatment with a low dosage of IL-2 subcutaneously, alternately with alpha-IFN. This treatment resulted in a hematologic and cytogenetic remission. He also developed a limited degree of chronic GVHD. At the latest follow-up at 20 months after the third course of lymphocyte infusions he is in continuous hematologic and cytogenetic remission. Furthermore, a qualitative PCR analysis for the bcr/abl translocation is negative.
Lönnqvist
B
B
Department of Hematology, Huddinge Hospital, Sweden.
Brune
M
M
Ljungman
P
P
D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004200:Diseases in Twins; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D011994:Recombinant Proteins; D012074:Remission Induction; D016879:Salvage Therapy; D014184:Transplantation, Homologous
D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins